Sophiris Bio Inc. (SHS.TO) is a Canadian urology company with operations based in San Diego developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), a large unsatisfied market. PRX302, the company’s lead candidate for BPH, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is planning to begin a pivotal trial by the end of 2012.
The pivotal trial is supported by a randomized, controlled Phase IIb study that met the objective and subjective endpoints used as the basis for current BPH drug approvals. Sophiris is advised by world-leading urologists, is backed by experienced investors, and is led by an experienced drug development team that has achieved more than twenty drug approvals including several blockbusters.